Efficacy and Safety of Ibrutinib for Chronic Graft-Versus-Host Disease: A Systematic Review.
Damai SantosaDaniel RizkyKevin TandartoIka KartiyaniVina YunarvikaDesta Nur Ewika ArdiniBudi SetiawanEko Adhi PangarsaCatharina SuhartiPublished in: Asian Pacific journal of cancer prevention : APJCP (2023)
The majority of studies have indicated that ibrutinib exhibits a high ORR and provides long-lasting responses, while also having manageable side effects.
Keyphrases